A contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma -: Analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgkin Study Group (GHSG)

被引:22
作者
Eich, Hans Theodor
Gossmann, Axel
Engert, Andreas
Kriz, Jan
Bredenfeld, Henning
Hansemann, Katja
Skripnitchenko, Roman
Brillant, Corinne
Pfistner, Beate
Staar, Susanne
Diehl, Volker
Mueller, Rolf-Peter
机构
[1] Univ Cologne, Dept Radiat Oncol, D-50924 Cologne, Germany
[2] Univ Cologne, Dept Radiol, D-50924 Cologne, Germany
[3] Univ Cologne, Dept Med Oncol, D-50924 Cologne, Germany
[4] Klinikum Bremen Mitte, Dept Radiat Oncol, Bremen, Germany
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 69卷 / 04期
关键词
Hodgkin's lymphoma; consolidative radiotherapy; panel; quality assurance;
D O I
10.1016/j.ijrobp.2007.04.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The role of radiotherapy (RT) after intensive chemotherapy in patients with advanced stage Hodgkin's lymphoma (HL) is still unclear. The German Hodgkin Study Group (GHSG) randomized HD12 trial was designed to test whether consolidative RT in the region of initial bulky disease and of residual disease is necessary after effective chemotherapy. A quality control program based on a multidisciplinary panel of radiation oncologists, radiologists, and medical oncologists who reviewed all patients' staging and restaging imaging was initiated. Methods and Materials: A total of 1661 patients aged 16 to 65 years with HL in Stage IIB (large mediastinal mass and/or E-lesions) or Stage III to IV were randomized from January 1999 to January 2003 according to a factorial design between: 8 esc.BEACOPP + RT (arm A), 8 esc.BEACOPP non-RT (arm B), 4+4BEACOPP + RT (arm C), 4+4BEACOPP non-RT (arm D). Results: In the fifth interim analysis, 1449 patients were eligible for the arm comparison with regard to RT. After a median observation time of 48 months the FFTF rate was 86% and the OS 92%. The FFTF was 95% in the RT arms A+C and 88 % in the non-RT arms B+D: no sequential significant difference. One thousand and eighty four patients were evaluated by the panel. The panel defined initial bulky disease in 800 patients and residual disease in 600 patients. The panel recommended continuation of therapy according to the randomization for 934 of 1084 patients and additive RT independently from the randomization arm for 145 of 1084 patients. Conclusions: The study showed that RT can be reduced substantially after effective chemotherapy. However, because of the irradiation of 10% of patients in the non-RT arms, equivalent effectiveness of a non-RT strategy cannot be proved. A substantial limitation of consolidative RT according to expert panel recommendations appears to be possible without reducing effectiveness. (c) 2007 Elsevier Inc.
引用
收藏
页码:1187 / 1192
页数:6
相关论文
共 19 条
  • [1] Involved-field radiotherapy for advanced Hodgkin's lymphoma
    Aleman, BMP
    Raemaekers, JMM
    Tirelli, U
    Bortolus, R
    van't Veer, MB
    Lybeert, MLM
    Keuning, JJ
    Carde, P
    Girinsky, T
    van der Maazen, RWM
    Tomsic, R
    Vovk, M
    van Hoof, A
    Demeestere, G
    Lugtenburg, PJ
    Thomas, J
    Schroyens, W
    De Boeck, K
    Baars, JW
    Kluin-Nelemans, JC
    Carrie, C
    Aoudjhane, M
    Bron, D
    Eghbali, H
    Smit, WGJM
    Meerwaldt, JH
    Hagenbeek, A
    Pinna, A
    Henry-Amar, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) : 2396 - 2406
  • [2] Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884)
    Aleman, BMP
    Girinsky, T
    van Der Maazen, RWM
    Strijk, S
    Meijnders, P
    Bortolus, R
    Olofsen-van Acht, MJJ
    Lybeert, MLM
    Lievens, Y
    Eghbali, H
    Noordijk, EM
    Tomsic, R
    Meerwaldt, JH
    Poortmans, PMP
    Smit, WGJM
    Pinna, A
    Henry-Amar, M
    Raemaekers, JMM
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (04): : 1184 - 1190
  • [3] BUNDESARZTEKAMM, 1992, DT ARZTEBL, V89, P3
  • [4] CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD
    CANELLOS, GP
    ANDERSON, JR
    PROPERT, KJ
    NISSEN, N
    COOPER, MR
    HENDERSON, ES
    GREEN, MR
    GOTTLIEB, A
    PETERSON, BA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) : 1478 - 1484
  • [5] CARBONE PP, 1971, CANCER RES, V31, P1860
  • [6] BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
    Diehl, V
    Sieber, M
    Ruffer, U
    Lathan, B
    Hasenclever, D
    Pfreundschuh, M
    Loeffler, M
    Lieberz, D
    Koch, P
    Adler, M
    Tesch, H
    [J]. ANNALS OF ONCOLOGY, 1997, 8 (02) : 143 - 148
  • [7] Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease
    Diehl, V
    Franklin, J
    Pfreundschuh, M
    Lathan, B
    Paulus, U
    Hasenclever, D
    Tesch, H
    Herrmann, R
    Dörken, B
    Müller-Hermelink, H
    Dühmke, E
    Loeffler, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (24) : 2386 - 2395
  • [8] DIEHL V, 1997, P AN M AM SOC CLIN, V16, pA2
  • [9] Dühmke E, 2001, J CLIN ONCOL, V19, P2905
  • [10] The HD12 panel of the German Hodgkin Lymphoma study Group (GHSG) -: A quality assurance program based on a multidisciplinary panel reviewing all patients' Imaging
    Eich, HT
    Staar, S
    Gossmann, A
    Engert, A
    Franklin, J
    Sieber, M
    Krug, B
    Diehl, V
    Lackner, KJ
    Müller, RP
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03): : 279 - 284